BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Adams was CEO at Aralez Pharmaceuticals Inc. and its predecessor Pozen Inc. Viral immuno-oncology company Candel Therapeutics...
BioCentury | Sep 19, 2016
Financial News

Advantagene completes venture financing

Advantagene Inc. , Auburndale, Mass. Business: Cancer Date completed: 2016-09-12 Type: Venture financing Raised: $14.2 million WIR Staff...
BioCentury | Sep 12, 2016
Financial News

Advantagene raises $14.2M

...Immuno-oncology company Advantagene Inc. (Auburndale, Mass.) raised $14.2 million in a series A round from undisclosed...
...Securities Corp. subsidiary of National Holdings Corp. (NASDAQ:NHLD) was the placement agent. The funding is Advantagene's...
...first significant outside investment since it was founded in 1999, CBO Stephen Rocamboli told BioCentury. Advantagene...
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...At least 12 companies have gene therapy products delivered using adenoviral vectors in clinical development: Advantagene...
BioCentury | Aug 9, 2012
Targets & Mechanisms

Screening for immunogenic cell death

...of tumor antigens to the host immune system," said Estuardo Aguilar-Cordova, CEO of Advantagene Inc. Advantagene's...
...Lou, K.-J. SciBX 5 (31); doi:10.1038/scibx.2012.808 Published online Aug. 9, 2012 Companies and Institutions Mentioned Advantagene...
BioCentury | May 30, 2011
Clinical News

ProstAtak: SPA received

...to begin the trial next quarter. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Valtrex valacyclovir. Advantagene...
Items per page:
1 - 6 of 6
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Adams was CEO at Aralez Pharmaceuticals Inc. and its predecessor Pozen Inc. Viral immuno-oncology company Candel Therapeutics...
BioCentury | Sep 19, 2016
Financial News

Advantagene completes venture financing

Advantagene Inc. , Auburndale, Mass. Business: Cancer Date completed: 2016-09-12 Type: Venture financing Raised: $14.2 million WIR Staff...
BioCentury | Sep 12, 2016
Financial News

Advantagene raises $14.2M

...Immuno-oncology company Advantagene Inc. (Auburndale, Mass.) raised $14.2 million in a series A round from undisclosed...
...Securities Corp. subsidiary of National Holdings Corp. (NASDAQ:NHLD) was the placement agent. The funding is Advantagene's...
...first significant outside investment since it was founded in 1999, CBO Stephen Rocamboli told BioCentury. Advantagene...
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...At least 12 companies have gene therapy products delivered using adenoviral vectors in clinical development: Advantagene...
BioCentury | Aug 9, 2012
Targets & Mechanisms

Screening for immunogenic cell death

...of tumor antigens to the host immune system," said Estuardo Aguilar-Cordova, CEO of Advantagene Inc. Advantagene's...
...Lou, K.-J. SciBX 5 (31); doi:10.1038/scibx.2012.808 Published online Aug. 9, 2012 Companies and Institutions Mentioned Advantagene...
BioCentury | May 30, 2011
Clinical News

ProstAtak: SPA received

...to begin the trial next quarter. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Valtrex valacyclovir. Advantagene...
Items per page:
1 - 6 of 6